Home > > > > > Report Detail

Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Chronic Obstructive Pulmonary Disease (COPD) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Chronic Obstructive Pulmonary Disease (COPD) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Chronic Obstructive Pulmonary Disease (COPD) outlook. It also includes the explanation of changing trends of epidemiology outlining the Chronic Obstructive Pulmonary Disease (COPD) scenario.

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Chronic Obstructive Pulmonary Disease (COPD) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

- The report covers detailed overview of Chronic Obstructive Pulmonary Disease (COPD) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The Chronic Obstructive Pulmonary Disease (COPD) Report assesses the disease risk and burden and highlights the unmet needs

- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

- 10 Year Forecast

- 7MM Coverage

- Total Cases in Chronic Obstructive Pulmonary Disease (COPD)

Key assessments

- Patient Segmentation in Chronic Obstructive Pulmonary Disease (COPD)

- Chronic Obstructive Pulmonary Disease (COPD) Risk & Burden

- Factors driving growth in a specific Chronic Obstructive Pulmonary Disease (COPD) patient population

Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2028

Table of Contents

1. Report Introduction
2. Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Chronic Obstructive Pulmonary Disease (COPD) in 2016
2.2. Patient Share Distribution of Chronic Obstructive Pulmonary Disease (COPD) in 2028
3. Disease Background and Overview: Chronic Obstructive Pulmonary Disease (COPD)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Chronic Obstructive Pulmonary Disease (COPD) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Chronic Obstructive Pulmonary Disease (COPD) in 7MM - By Countries
5. Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.1.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) *
5.1.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.1.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.4.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.4.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.4.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.5.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.5.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.5.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.6.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.6.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.6.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.7.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.7.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.7.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.8.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.8.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.8.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD)
5.9.3. Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.9.4. Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD)*
5.9.5. Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD)
6. Unmet Needs of the Chronic Obstructive Pulmonary Disease (COPD)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in 7MM
Table 2: Total Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028) *
Table 14: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Chronic Obstructive Pulmonary Disease (COPD) in Japan (2016-2028)

  • Global Carbocisteine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 102
    According to our LPI (LP Information) latest study, the global Carbocisteine market size was valued at US$ 55 million in 2023. With growing demand in downstream market, the Carbocisteine is forecast to a readjusted size of US$ 76 million by 2030 with a CAGR of 4.9% during review period. The research report highlights the growth potential of the global Carbocisteine market. Carbocisteine are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • Global Bovine Respiratory Disease Treatment Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 120
    Report Overview: Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired host immunity, inadequate housing conditions, and environmental factors. The major factor leading to bovine respiratory diseases are host factors, environmental factors, and direct influence of infectious agents such as virus, bacteria, and parasites. However, due to increasing consumption of milk and beef products, the need for......
  • Global Ambroxol Market Research Report 2023
    Published: 01-Dec-2023        Price: US 2900 Onwards        Pages: 91
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Ambroxol market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Teva - Bayer - Novartis - Mylan - Bidachem - Hanmi - Hexal Pharma - Sris Pharmaceuticals - Hubei Ocean Biotechnology - DM Pharma......
  • Global Carbocisteine Professional Survey Report 2023, Forecast to 2028
    Published: 23-Nov-2023        Price: US 3280 Onwards        Pages: 101
    Carbocisteine is a type of medicine called a mucolytic. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to de......
  • Global Carbocisteine Market Research Report 2023, Forecast to 2028
    Published: 23-Nov-2023        Price: US 2680 Onwards        Pages: 136
    Carbocisteine is a type of medicine called a mucolytic. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to de......
  • Global Bovine Respiratory Disease Treatment Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 09-Nov-2023        Price: US 3380 Onwards        Pages: 99
    Market Overview of Global Bovine Respiratory Disease Treatment market: According to our latest research, the global Bovine Respiratory Disease Treatment market looks promising in the next 5 years. As of 2022, the global Bovine Respiratory Disease Treatment market was estimated at USD 1748.69 million, and it's anticipated to reach USD 2423.79 million in 2028, with a CAGR of 5.59% during the forecast years. Bovine respiratory disease (BRD) is a multifactorial and complex diseas......
  • Respiratory Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 200
    Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of respiratory deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding......
  • Global Drugs For Respiratory Syncytial Virus (Rsv) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Sep-2023        Price: US 3380 Onwards        Pages: 106
    Market Overview of Global Drugs For Respiratory Syncytial Virus (Rsv) market: According to our latest research, the global Drugs For Respiratory Syncytial Virus (Rsv) market looks promising in the next 5 years. As of 2022, the global Drugs For Respiratory Syncytial Virus (Rsv) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and......
  • Global Ambroxol Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Sep-2023        Price: US 3380 Onwards        Pages: 127
    Market Overview of Global Ambroxol market: According to our latest research, the global Ambroxol market looks promising in the next 5 years. As of 2022, the global Ambroxol market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Ambroxol market, with a systematical descriptio......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs